...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Tropical Medicine and Hygiene >Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants
【24h】

Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants

机译：对坦桑尼亚成人，青少年，儿童和婴儿的坦桑尼亚成年人，青少年疫苗，PFSPZ疫苗的安全性和差异抗体和T细胞应答

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In 2016, there were more cases and deaths caused by malaria globally than in 2015. An effective vaccine would be an ideal additional tool for reducingmalaria's impact. Sanaria (R) PfSPZVaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) has been well tolerated and safe in malaria naive and experienced adults in the United States and Mali and protective against controlled human malaria infection with Pf in the United States and field transmission of Pf in Mali, but had not been assessed in younger age groups. We, therefore, evaluated PfSPZ Vaccine in 93 Tanzanians aged 45 years to 6 months in a randomized, double-blind, normal saline placebo-controlled trial. There were no significant differences in adverse events between vaccinees and controls or between dosage regimens. Because all age groups received three doses of 9.0 x 10(5) PfSPZ of PfSPZ Vaccine, immune responses were compared at this dosage. Median antibody responses against Pf circumsporozoite protein and PfSPZ were highest in infants and lowest in adults. T-cell responses were highest in 6-10-year olds after one dose and 1-5-year olds after three doses; infants had no significant positive T-cell responses. The safety data were used to support initiation of trials in > 300 infants in Kenya and Equatorial Guinea. Because PfSPZ Vaccine-induced protection is thought to be mediated by T cells, the T-cell data suggest PfSPZ Vaccine may be more protective in children than in adults, whereas infants may not be immunologically mature enough to respond to the PfSPZ Vaccine immunization regimen assessed.
机译：2016年，全球疟疾造成的案件和死亡造成的案例和死亡造成的患者和死亡是有效的疫苗将是redoptmalaria的影响的理想额外工具。 Sanaria（r）Pfspzvaccine，由辐射衰减，无菌，纯化的冷冻保存的疟原虫（PF）孢子（SPZ）组成，在美国和马里的疟疾天真和经验丰富的成年人中耐受良好和安全，并防止受控人类疟疾用PF在美国的PF感染和马里PF的田间传播，但尚未评估较年轻的年龄群体。因此，我们在45岁以上的93岁至6个月内评估了PFSPZ疫苗，在随机的双盲，正常盐水排放试验中进行了6个月。疫苗和对照之间的不良事件或剂量方案之间没有显着差异。由于所有年龄组接受了三剂量的9.0×10（5）个PFSPZ疫苗的PFSPz，因此在该剂量上比较免疫应答。对PF环孢子蛋白蛋白和PFSPZ的中值抗体反应在婴儿和成人中最低。在三剂后1-5岁后，6-10岁的T细胞应答最高;婴儿没有显着的阳性T细胞反应。安全数据用于支持在肯尼亚和赤道几内亚在> 300婴儿的试验开始。由于PFSPZ疫苗诱导的保护被认为是由T细胞介导的，所以T细胞数据表明PFSPZ疫苗在儿童中可能比在成人中更具保护，而婴儿可能不足以响应评估的PFSPZ疫苗免疫方案的免疫学会成熟。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号